Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEYFORTUS vs BENLYSTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapy,Lupus nephritis (in combination with standard therapy)
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Protein binding is approximately 99.5%, primarily to albumin.
Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
SC: ~82% relative to IV; IV: 100%.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD. Use caution and consider benefit-risk.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
Not indicated for geriatric population; no dosing recommendations available.
No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.
No black box warning.
No FDA black box warning.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Hypersensitivity reactions including anaphylaxis,Infusion reactions,Increased risk of serious infections, including tuberculosis and opportunistic infections,Malignancy risk (potential),Hypogammaglobulinemia,Depression and suicidality
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
None known; caution in patients with severe active infections.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
No known food interactions. May be taken without regard to meals.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as Ig G crosses placenta after 13 weeks gestation. Third trimester: Ig G actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
No dose adjustment recommended based on pregnancy pharmacokinetic changes. However, caution advised due to limited data. Dose may need adjustment if concomitant immunosuppressants used.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
BENLYSTA (belimumab) is a BLy S-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
Report any signs of allergic reaction during or after infusion immediately.,Avoid live vaccines during treatment and for at least 30 days after stopping.,Inform doctor of any new or worsening neurological symptoms.,Use effective contraception during therapy and for 4 months after last dose.,Do not stop or change dose without consulting your rheumatologist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEYFORTUS vs BENLYSTA, answered by our medical review team.
BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. BENLYSTA is a Monoclonal Antibody that works by Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEYFORTUS and BENLYSTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. The standard adult dose of BENLYSTA is: 10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEYFORTUS and BENLYSTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. BENLYSTA is classified as Category C. First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell dep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.